[1] ZHANG X,BOLCK H A,RUPP N J,et al.Genomic alterations and diagnosis of renal cancer[J].Virchows Arch,2024,484(2):323-337. [2] CHEN T Y,MIHALOPOULOS M,ZULUAGA L,et al.Cl-inical significance of extracellular vesicles in prostate and renal cancer[J].Int J Mol Sci,2023,24(19):14713-14738. [3] POPŁAWSKI P,ZARYCHTA-WIŠNIEWSKA W,BURDZI-ńSKA A,et al.Renal cancer secretome induces migration of mesenchymal stromal cells[J].Stem Cell Res Ther,2023,14(1):200-212. [4] YI M,LI T,NIU M,et al.Exploiting innate immunity for cancer immunotherapy[J].Mol Cancer,2023,22(1):187-241. [5] DOLTON G,RIUS C,WALL A,et al.Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy[J].Cell,2023,186(16):3333-3349. [6] GILES J R,GLOBIG A M,KAECH S M,et al.CD8+T ce-lls in the cancer-immunity cycle[J].Immunity,2023,56(10):2231-2253. [7] YUE M,HU S,SUN H,et al.Extracellular vesicles rem-odel tumor environment for cancer immunotherapy[J].Mol Cancer,2023,22(1):203-222. [8] NAJAFI S,MAJIDPOOR J,MORTEZAEE K.Extracellular vesicle-based drug delivery in cancer immunotherapy[J].Drug Deliv Transl Res,2023,13(11):2790-2806. [9] MCLANE L M,ABDEL-HAKEEM M S,WHERRY E J.CD8+T cell exhaustion during chronic viral infection and cancer[J].Annu Rev Immunol,2019,26(37):457-495. [10] MEISER P,KNOLLE M A,HIRSCHBERGER A,et al.A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity[J].Cancer Cell,2023,41(8):1498-1515 [11] PARK J,HSUEH PC,LI Z,et al.Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity[J].Immunity,2023,56(1):32-42. [12] JIA D,WANG Q,QI Y,et al.Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer[J].Cell,2024,187(7):1651-1665. [13] ESCOBAR G,TOOLEY K,OLIVERAS JP,et al.Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy[J].Cancer Cell,2023,41(9):1662-1679. [14] LI B,CAO Y,SUN M,FENG H.Expression,regulation,and function of exosome-derived miRNAs in cancer progression and therapy[J].FASEB J,2021,35(10):e21916-e21929. [15] ZHANG L,YU D.Exosomes in cancer development,metastasis,and immunity[J].Biochim Biophys Acta Rev Cancer,2019,1871(2):455-468. [16] HU Z,CHEN G,ZHAO Y,et al.Exosome-derived circCCAR1 promotes CD8+T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma[J].Mol Cancer,2023,22(1):55-75. [17] LI D,ZHOU X,XU W,et al.Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD-L1[J].Cancer Med,2023,12(15):16405-16415. [18] QU L,DING J,CHEN C,et al.Exosome-transmitted incARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA[J].Cancer Cell,2016,29(5):653-668. [19] DING M,ZHAO X,CHEN X,et al.Cancer-associated fibroblasts promote the stemness and progression of renal cell carcinoma via exosomal miR-181d-5p[J].Cell Death Discov,2022,8(1):439-454. [20] BOUSSIOS S,DEVO P,GOODALL I C A,et al.Exosomes in the Diagnosis and Treatment of Renal Cell Cancer[J].Int J Mol Sci,2023,24(18):14356-14378. [21] YI M,ZHENG X,NIU M,et al.Combination strategies with PD-1/PD-L1 blockade:current advances and future directions[J].Mol Cancer,2022,21(1):28-54. [22] HUANG C,REN S,CHEN Y,et al.PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance[J].Sci Adv,2023,9(21):eade4186-eade4205. [23] YUAN Y,WANG L,GE D,et al.Exosomal O-GlcNAc tr-ansferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8+ T cells[J].Cancer Lett,2021,5(500):98-106. |